预防性输卵管卵巢切除术在遗传性卵巢癌中的应用

doi:10.19401/j.cnki.1007-3639.2022.11.002

中国癌症杂志 ›› 2022, Vol. 32 ›› Issue (11): 1044-1048.doi: 10.19401/j.cnki.1007-3639.2022.11.002

预防性输卵管卵巢切除术在遗传性卵巢癌中的应用

冯征¹^,²(), 温灏¹^,²()

1.复旦大学附属肿瘤医院肿瘤妇科，复旦大学上海医学院肿瘤学系，上海 200032

收稿日期:2022-10-23 修回日期:2022-11-15 出版日期:2022-11-30 发布日期:2022-12-14
通信作者: 温灏
作者简介:冯征（ORCID: 0000-0003-2561-3869），博士，主治医师。
温灏，医学博士，副主任医师，复旦大学附属肿瘤医院肿瘤妇科行政副主任。中国抗癌协会妇科肿瘤专业委员会委员、秘书长，中国抗癌协会妇科肿瘤科普教育基地专业委员会委员、秘书长，中国抗癌协会肿瘤标志专业委员会妇科肿瘤标志物专家学组副组长，上海市抗癌协会青年理事会理事，上海市抗癌协会肿瘤药物临床研究专业委员会委员，上海市医学会妇科肿瘤学分会卵巢癌学组副组长。Gynecology and Pelvic Medicine编委，《现代妇产科进展》《肿瘤药学》编委。

Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer

FENG Zheng¹^,²(), WEN Hao¹^,²()

1. Department of Gynecological Oncology, Fudan University Shanghai Cancer Center
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

Received:2022-10-23 Revised:2022-11-15 Published:2022-11-30 Online:2022-12-14
Contact: WEN Hao

摘要/Abstract

摘要：

卵巢癌是危害女性生命健康的常见疾病。目前尚无有效的卵巢癌筛查及早期诊断方法，多数卵巢癌发现时已为晚期，总体疗效并不理想。流行病学研究显示，携带相关基因突变的女性罹患卵巢癌的概率显著提高。因此，对其进行预防干预十分重要。预防性输卵管卵巢切除术是目前降低高风险女性卵巢癌发病率的最有效手段。手术和病理取材的规范性是预防性手术发挥作用的有力保障。本文旨在探讨预防性手术在遗传性卵巢癌中应用的现状及争议，以期使预防性手术的开展更加规范化、个体化。

关键词: 卵巢癌, 预防性输卵管卵巢切除术, 遗传性卵巢癌

Abstract:

Ovarian cancer is one of the most common and lethal diseases among females. Due to the difficulty of surveillance and early detection, most ovarian cancers were diagnosed at advanced stage with poor outcomes. Epidemiological studies indicate that women with deleterious gene mutations have higher susceptibility of ovarian cancer. Thus, it is pivotal to prevent its occurrence. Risk-reducing salpingo-oophorectomy is the most effective method to prevent women at high risk from ovarian cancer. It depends on the standardization of the surgical and pathological procedure. In this article, we aimed to elucidate the current status and controversy of this risk-reducing surgery.

Key words: Ovarian cancer, Risk-reducing salpingo-oophorectomy, Hereditary ovarian cancer

中图分类号:

R737.31

冯征, 温灏. 预防性输卵管卵巢切除术在遗传性卵巢癌中的应用[J]. 中国癌症杂志, 2022, 32(11): 1044-1048.

FENG Zheng, WEN Hao. Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer[J]. China Oncology, 2022, 32(11): 1044-1048.

参考文献 30

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	CHEN W Q, ZHENG R S, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
[3]	BEREK J S, KEHOE S T, KUMAR L, et al. Cancer of the ovary, fallopian tube, and peritoneum[J]. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet, 2018, 143(Suppl 2): 59-78.
[4]	SOWTER H M, ASHWORTH A. BRCA1 and BRCA2 as ovarian cancer susceptibility genes[J]. Carcinogenesis, 2005, 26(10): 1651-1656. doi: 10.1093/carcin/bgi136
[5]	MAVADDAT N, PEOCK S, FROST D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE[J]. J Natl Cancer Inst, 2013, 105(11): 812-822. doi: 10.1093/jnci/djt095
[6]	HALL M J, OBEID E I, SCHWARTZ S C, et al. Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond[J]. Gynecol Oncol, 2016, 140(3): 565-574. doi: 10.1016/j.ygyno.2016.01.019
[7]	PENNINGTON K P, WALSH T, HARRELL M I, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas[J]. Clin Cancer Res, 2014, 20(3): 764-775. doi: 10.1158/1078-0432.CCR-13-2287 pmid: 24240112
[8]	DALY M B, PAL T, BERRY M P, et al. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(1): 77-102. doi: 10.6004/jnccn.2021.0001
[9]	KURMAN R J, SHIH I M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory[J]. Am J Surg Pathol, 2010, 34(3): 433-443. doi: 10.1097/PAS.0b013e3181cf3d79 pmid: 20154587
[10]	ACOG committee opinion no. 774: opportunistic salpingectomy as a strategy for epithelial ovarian cancer prevention[J]. Obstet Gynecol, 2019, 133(4): e279-e284. doi: 10.1097/AOG.0000000000003164
[11]	DOMINGUEZ-VALENTIN M, SAMPSON J R, SEPPÄLÄ T T, et al. Cancer risks by gene, age, and gender in 6 350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database[J]. Genet Med, 2020, 22(1): 15-25.
[12]	SONG H L, DICKS E M, TYRER J, et al. Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer[J]. J Med Genet, 2021, 58(5): 305-313. doi: 10.1136/jmedgenet-2019-106739
[13]	WU N Y Y, FANG C, HUANG H S, et al. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions[J]. Mod Pathol, 2020, 33(1): 29-37. doi: 10.1038/s41379-019-0370-1
[14]	SHU C A, PIKE M C, JOTWANI A R, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations[J]. JAMA Oncol, 2016, 2(11): 1434-1440. doi: 10.1001/jamaoncol.2016.1820
[15]	STEENBEEK M P, HARMSEN M G, HOOGERBRUGGE N, et al. Association of salpingectomy with delayed oophorectomy versus salpingo-oophorectomy with quality of life in BRCA1/2 pathogenic variant carriers: a nonrandomized controlled trial[J]. JAMA Oncol, 2021, 7(8): 1203-1212. doi: 10.1001/jamaoncol.2021.1590
[16]	MEDEIROS F, MUTO M G, LEE Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome[J]. Am J Surg Pathol, 2006, 30(2): 230-236. pmid: 16434898
[17]	FOLKINS A K, JARBOE E A, SALEEMUDDIN A, et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations[J]. Gynecol Oncol, 2008, 109(2): 168-173. doi: 10.1016/j.ygyno.2008.01.012
[18]	VISVANATHAN K, SHAW P, MAY B J, et al. Fallopian tube lesions in women at high risk for ovarian cancer: a multicenter study[J]. Cancer Prev Res (Phila), 2018, 11(11): 697-706. doi: 10.1158/1940-6207.CAPR-18-0009
[19]	AKAHANE T, MASUDA K, HIRASAWA A, et al. TP53 variants in p53 signatures and the clonality of STICs in RRSO samples[J]. J Gynecol Oncol, 2022, 33(4): e50. doi: 10.3802/jgo.2022.33.e50 pmid: 35557033
[20]	LÕHMUSSAAR K, KOPPER O, KORVING J, et al. Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids[J]. Nat Commun, 2020, 11(1): 2660. doi: 10.1038/s41467-020-16432-0 pmid: 32461556
[21]	VAN DER HOEVEN N M A, VAN WIJK K, BONFRER S E, et al. Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review[J]. Clin Oncol (R Coll Radiol), 2018, 30(8): 463-471. doi: S0936-6555(18)30209-7 pmid: 29691126
[22]	PATRONO M G, INIESTA M D, MALPICA A, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review[J]. Gynecol Oncol, 2015, 139(3): 568-572. doi: 10.1016/j.ygyno.2015.09.018 pmid: 26407480
[23]	CHENG A S, LI L, WU M, et al. Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2020, 46(1): 139-147. doi: 10.1016/j.ejso.2019.09.002
[24]	RUSH S K, SWISHER E M, GARCIA R L, et al. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: a large prospective single institution experience[J]. Gynecol Oncol, 2020, 157(2): 514-520. doi: S0090-8258(20)30101-3 pmid: 32199636
[25]	SHERMAN M E, PIEDMONTE M, MAI P L, et al. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199[J]. J Clin Oncol, 2014, 32(29): 3275-3283. doi: 10.1200/JCO.2013.54.1987 pmid: 25199754
[26]	DOWDY S C, STEFANEK M, HARTMANN L C. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy[J]. Am J Obstet Gynecol, 2004, 191(4): 1113-1123. pmid: 15507929
[27]	STEENBEEK M P, VAN BOMMEL M H D, BULTEN J, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis[J]. J Clin Oncol, 2022, 40(17): 1879-1891. doi: 10.1200/JCO.21.02016
[28]	VAN WINDEN L J, VERMEULEN R F M, VAN DEN NOORT V, et al. Changes in sex steroids and relation with menopausal complaints in women undergoing risk-reducing salpingo-oophorectomy[J]. J Endocr Soc, 2022, 6(6): bvac069. doi: 10.1210/jendso/bvac069
[29]	MOSS K M, MISHRA G D, KREJANY E O, et al. What happens after menopause? (WHAM): a prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy[J]. Gynecol Oncol, 2022, 167(1): 58-64. doi: 10.1016/j.ygyno.2022.07.029
[30]	MAI P L, MILLER A, BLACK A, et al. Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study[J]. Am J Obstet Gynecol, 2022, 227(1): 61. e1-61.61.e18.

预防性输卵管卵巢切除术在遗传性卵巢癌中的应用

Risk-reducing salpingo-oophorectomy for hereditary ovarian cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵明明, 王天佑, 王超. 妇科恶性肿瘤术后激素替代治疗的研究进展[J]. 中国癌症杂志, 2022, 32(11): 1098-1104.
[2]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[3]	朱　俊, 吴小华. 2020年度妇科恶性肿瘤最新研究进展及展望[J]. 中国癌症杂志, 2021, 31(4): 250-256.
[4]	蔡树模, 汤　洁, 黄　啸, 黄晓炜, 刘素萍, 柯桂好, 郑　重, 程　玺, 唐美琴. 铂类药物敏感复发卵巢癌患者的三步化疗法附20例分析[J]. 中国癌症杂志, 2021, 31(4): 330-334.
[5]	刘懿萱 , 文泽轩 , 郭　林 , 卢仁泉 . TTK1在卵巢癌铂类耐药中的生物学功能分析[J]. 中国癌症杂志, 2021, 31(3): 182-191.
[6]	俞　弋, 丛　青, 徐丛剑, 姜　伟. PAFR对卵巢癌细胞顺铂敏感性的影响及机制研究[J]. 中国癌症杂志, 2021, 31(11): 1063-1071.
[7]	赵海云, 吴小华. 免疫治疗在卵巢癌中的应用研究进展[J]. 中国癌症杂志, 2020, 30(7): 538-545.
[8]	王晓琴, 傅鑫蕾, 马如越, 杨丽娜, 陈亚萍, 张丽文. Sema3A通过调控上皮-间质转化/基质金属蛋白酶-2参与上皮性卵巢癌转移[J]. 中国癌症杂志, 2020, 30(6): 428-434.
[9]	冯　征, 吴小华　. PARP抑制剂用于铂敏感复发卵巢癌患者维持治疗的血液学毒性概述[J]. 中国癌症杂志, 2020, 30(4): 299-304.
[10]	中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会. 上皮性卵巢癌PARP抑制剂相关生物标志物检测的中国专家共识[J]. 中国癌症杂志, 2020, 30(10): 841-848.
[11]	吴小华，张　剑，尹如铁，娄　阁，高雨农. 优化卵巢癌Ⅰ期临床研究管理中国专家经验[J]. 中国癌症杂志, 2019, 29(5): 321-327.
[12]	王珏,杜琰,王烨菁,等. 2002—2011年上海市原卢湾区居民卵巢癌的发病和死亡资料分析[J]. 中国癌症杂志, 2018, 28(6): 407-410.
[13]	周韵娇,王婧姝,梁　凡,等. TGF-β1通过TRAF6活化Notch3信号通路促进卵巢癌细胞迁移和侵袭的研究[J]. 中国癌症杂志, 2018, 28(2): 98-104.
[14]	郭芳芳,冯文娟,李冬青,等. 机器人与腹腔镜手术治疗早期卵巢癌的临床比较[J]. 中国癌症杂志, 2018, 28(2): 151-155.
[15]	胡宏峰,卢仁泉,胡　娟,等. 卵巢癌患者血清唾液酸含量检测的价值[J]. 中国癌症杂志, 2017, 27(7): 588-592.